The Liver Meeting

The Liver Meeting

November 13, 2014
1 min read

Long-term efficacy, safety of tenofovir disoproxil fumarate for chronic HBV confirmed

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

BOSTON — Long-term results from two phase 3 trials of tenofovir disoproxil fumarate for chronic hepatitis B demonstrated safety and efficacy of the treatment with no resistance through 8 years, according to data presented at a plenary session during The Liver Meeting.

“Tenofovir disoproxil fumarate is a potent first-line treatment for patients with chronic hepatitis B,” Maria Buti, MD, of Vall d'Hebron University Hospital in Barcelona, Spain, said in a presentation. “Here we present efficacy, safety and resistance results over 8 years of tenofovir disoproxil fumarate treatment.”

Maria Buti, MD

Maria Buti

Continuing the extension phase of two phase 3 studies whose data through year 5 was reported previously, Buti and colleagues evaluated the remaining 412 patients (64% of the original cohort). Patients had hepatitis B e antigen (HBeAg)-negative (n=266) and HBeAg-positive (n=146) chronic hepatitis B and continued on open label Tenofovir disoproxil fumarate (TDF) through year 8 after an initial 48-week comparative study of TDF and adefovir dipivoxil. The researchers evaluated these patients for treatment safety and efficacy every 3 months, tested them for resistance once a year, and began testing bone mineral density once a year starting at year 4.

Eight-year results showed that durable viral suppression was maintained, seven additional patients had loss of HBsAG beginning in year 5 and no resistance to TDF was detected throughout the study period. Overall response was observed in 75% of HBeAg-negative patients, and 58% of HBeAg-positive patients. Confirmed renal events, including increase in serum creatinine (at least 0.5 mg) or serum phosphorous (less than 2 mg/dL), or creatinine clearance (less than 50mL/min) occurred in 2.2% of patients, and bone mineral density scores of the hip and spine remained stable from year 4 to 8.

“Over an 8 year treatment period with tenofovir disoproxil fumarate, virological and serological responses were durable,…virological suppression was consistently maintained in almost all the patients…and no TDF resistance was detected through 8 years,” Buti said. “Long-term TDF treatment was well tolerated, renal events were uncommon… and no clinically relevant bone loss was observed between year 4 and year 8.” 

For more information:

Marcellin P. Abstract 229. Presented at: The Liver Meeting, Nov. 7-11, 2014; Boston, MA.

Disclosure: See the abstract for a full list of relevant financial disclosures.